Aldeyra Therapeutics, Inc.(ALDX)Earnings, Financials & Key RatiosAldeyra Therapeutics, Inc. (ALDX) stock price & volume — 10-year historical chart
Investment Thesis • Updated 2026Q1
the company's persistent cash burn, evidenced by a $5.1 million negative operating cash flow in 2026Q1, suggests significant liquidity risks for long-term shareholders.
Aldeyra Therapeutics, Inc. (ALDX) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Aldeyra Therapeutics, Inc. (ALDX) EPS & revenue vs analyst estimates — last 4 quarters
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 7, 2026 | $0.06vs $0.13+53.8% | — |
| Q1 2026 | Feb 27, 2026 | $0.11vs $0.14+21.4% | —vs $5M |
| Q4 2025 | Nov 5, 2025 | $0.13vs $0.17+23.5% | —vs $24M |
| Q3 2025 | Aug 7, 2025 | $0.16vs $0.21+23.8% | — |
Recent stock market news and headlines for Aldeyra Therapeutics, Inc. (ALDX)
Highly Experienced US-Based Public Markets Leader Strengthens Team as Company Drives Late Stage Development of LEVI-04 for Osteoarthritis Highly Experienced US-Based Public Markets Leader Strengthens Team as Company Drives Late Stage Development of LEVI-04 for Osteoarthritis
Key metrics vs top competitors for Aldeyra Therapeutics, Inc. (ALDX)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $2.23 | $134.52M | -3.98 | — | — | -58.73% | — | |
| $10.33 | $2.26B | -7.27 | -18.67% | -558.24% | -64.55% | — | |
| $1.51 | $33.11M | -0.46 | — | — | -1335.64% | — | |
| $81.57 | $9.68B | 31.86 | 37.55% | 23.13% | 126.27% | — | |
| $56.56 | $6.78B | -17.19 | — | — | -163.52% | — | |
| $323.95 | $9.36B | -24.03 | -100% | — | -43.02% | — |
Aldeyra Therapeutics, Inc. (ALDX) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Aldeyra Therapeutics, Inc. (ALDX) SEC filings — annual & quarterly reports (10-K, 10-Q)
Apr 20, 2026·SEC
Apr 1, 2026·SEC
Mar 17, 2026·SEC
Get notified when ALDX posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Aldeyra Therapeutics, Inc. (ALDX) stock FAQ — growth, dividends, profitability & financials explained
Aldeyra Therapeutics, Inc. (ALDX) reported a net loss of $27.4M for fiscal year 2025.
Aldeyra Therapeutics, Inc. (ALDX) has a return on equity (ROE) of -58.7%. Negative ROE indicates the company is unprofitable.
Aldeyra Therapeutics, Inc. (ALDX) had negative free cash flow of $26.0M in fiscal year 2025, likely due to heavy capital investments.
